Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Semax research overview

Semax is a synthetic analogue based on the ACTH(4–7) fragment with a C-terminal Pro-Gly-Pro sequence.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Semax?

Rat studies have measured BDNF-associated changes and transcriptomic responses in basal-forebrain, focal-ischemia, and acute-stress models.

Research category

Neuro research

Study models represented

Rat brain, focal-ischemia, and acute-stress models

Names in the literature

ACTH(4-7)PGP; Met-Glu-His-Phe-Pro-Gly-Pro

Primary boundary

Animal molecular endpoints do not establish human clinical outcomes.

What does the selected evidence support?

Changes in rat gene expression or protein measurements do not establish cognitive, neuroprotective, or therapeutic effects in people.

Primary sources

1. Dolotov et al., Bulletin of Experimental Biology and Medicine (2006) — BDNF-associated measurements in rat basal forebrain. DOI: 10.1007/s10517-006-0216-5
2. Medvedeva et al., BMC Genomics (2014) — Genome-wide expression analysis in a rat focal-cerebral-ischemia model. DOI: 10.1186/1471-2164-15-228
3. Filippenkov et al., Genes (2021) — RNA-sequencing study in a rat acute-stress model. DOI: 10.3390/genes12091447

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Semax product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.